A review of pulmonary toxicity of electronic cigarettes in the context of smoking: A focus on inflammation

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 8, 2017, Pages 1175-1191

  Shields, Peter G ^a   Berman, Micah ^a   Brasky, Theodore M ^a   Freudenheim, Jo L ^b   Mathe, Ewy ^c   McElroy, Joseph P ^c   Song, Min Ae ^a   Wewers, Mark D ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MESSENGER RNA; MICRORNA; NICOTINE; NITRIC OXIDE;

AEROSOL; BRONCHOSCOPY; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; ELECTRONIC CIGARETTE; FLAVOR; GENE EXPRESSION; HUMAN; LABORATORY TEST; LUNG CANCER; LUNG PARENCHYMA; LUNG TOXICITY; METABOLOMICS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SMOKING CESSATION; FEMALE; INFLAMMATION; MALE; PROCEDURES;

ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMATION; MALE; SMOKING; TOBACCO SMOKING;

EID: 85026846106     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0358     Document Type: Review

References (271)

1. Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific review. Circulation 2014;129:1972-86.
2. Adams S. E-cigarettemanufacturers say new regulations will devastate the industry. Forbes 2016. https://www.forbes.com/sites/susanadams/2016/05/05/e-cigarette-manufacturers-say-new-regulations-will-devastate-theindustry/# 14ceff8b66d4.
3. Singh T, Kennedy S, Marynak K, Persoskie A, Melstrom P, King BA. Characteristics of electronic cigarette use among middle and high school students - United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65: 1425-9.
4. Singh T, Arrazola RA, Corey CG, Husten CG, Neff LJ, Homa DM, et al. Tobacco use among middle and high school students-United States, 2011-2015. MMWR Morb Mortal Wkly Rep 2016;65:361-7.
5. Kasza KA, Ambrose BK, Conway KP, Borek N, Taylor K, Goniewicz ML, et al. Tobacco-product use by adults and youths in the United States in 2013 and 2014. N Engl J Med 2017;376:342-53.
6. Spindle TR, Hiler MM, Cooke ME, Eissenberg T, Kendler KS, Dick DM. Electronic cigarette use and uptake of cigarette smoking: a longitudinal examination of U.S. college students. Addict Behav 2017;67:66-72.
7. Huang LL, Kowitt SD, Sutfin EL, Patel T, Ranney LM, Goldstein AO. Electronic cigarette use among high school students and its association with cigarette use and smoking cessation, North Carolina Youth Tobacco Surveys, 2011 and 2013. Prev Chronic Dis 2016; 13:E103.
8. Weaver SR, Majeed BA, Pechacek TF, Nyman AL, Gregory KR, Eriksen MP. Use of electronic nicotine delivery systems and other tobacco products among USA adults, 2014: results from a national survey. Int J Public Health 2016;61:177-88.
9. McMillen RC, Gottlieb MA, Shaefer RM, Winickoff JP, Klein JD. Trends in electronic cigarette use among U.S. adults: use is increasing in both smokers and nonsmokers. Nicotine Tob Res 2015;17: 1195-202.
10. Patel D, Davis KC, Cox S, Bradfield B, King BA, Shafer P, et al. Reasons for current E-cigarette use among U.S. adults. Prev Med 2016;93:14-20.
11. Smith DM, Bansal-Travers M, Huang J, Barker D, Hyland AJ, Chaloupka F. Association between use of flavoured tobacco products and quit behaviours: findings from a cross-sectional survey of US adult tobacco users. Tob Control 2016;25 Suppl 2:ii73-ii80.
12. Dinakar C, O'Connor GT. The health effects of electronic cigarettes. N Engl J Med 2016;375:1372-81.
13. Bareham D, Ahmadi K, Elie M, Jones AW. E-cigarettes: controversies within the controversy. Lancet Respir Med 2016;4:868-9.
14. Correa JB, Ariel I, Menzie NS, Brandon TH. Documenting the emergence of electronic nicotine delivery systems as a disruptive technology in nicotine and tobacco science. Addict Behav 2017;65:179-84.
15. Fairchild AL, Bayer R. Smoke and fire over e-cigarettes. Science 2015; 347:375-6.
16. McKee M, Chapman S, Daube M, Glantz S. The debate on electronic cigarettes. Lancet 2014;384:2107.
17. Hajek P. Electronic cigarettes have a potential for huge public health benefit. BMC Med 2014;12:225.
18. Oh AY, Kacker A. Do electronic cigarettes impart a lower potential disease burden than conventional tobacco cigarettes?: Review on e-cigarette vapor versus tobacco smoke: Review on E-Cigarette Vapor Versus Tobacco Smoke. Laryngoscope 2014;124:2702-6.
19. McKee M. Electronic cigarettes: peering through the smokescreen. Postgrad Med J 2014;90:607-9.
20. Rowell TR, Tarran R. Will chronic e-cigarette use cause lung disease? Am J Physiol Lung Cell Mol Physiol 2015;309:L1398-409.
21. Majeed BA, Weaver SR, Gregory KR, Whitney CF, Slovic P, Pechacek TF, et al. Changing perceptions of harm of E-cigarettes among U.S. adults, 2012-2015. Am J Prev Med 2017;52:331-8.
22. Kaisar MA, Prasad S, Liles T, Cucullo L. A decade of e-cigarettes: limited research & unresolved safety concerns. Toxicology 2016;365: 67-75.
23. Xu Y, Guo Y, Liu K, Liu Z, Wang X. E-cigarette awareness, use, and harm perception among adults: a meta-analysis of observational studies. PLoS One 2016;11:e0165938.
24. Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, et al. Electronic nicotine delivery systems: a policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res 2015;21: 514-25.
25. Schraufnagel DE, Blasi F, Drummond MB, Lam DCL, Latif E, Rosen MJ, et al. Electronic cigarettes. A position statement of the Forum of International Respiratory Societies. Am J Respir Crit Care Med 2014; 190:611-8.
26. McCarthyM. American Medical Association calls for stricter regulation of electronic cigarettes. BMJ 2014;348:g4034.
27. Tomashefski A. The perceived effects of electronic cigarettes on health by adult users: a state of the science systematic literature review. J Am Assoc Nurse Pract 2016;28:510-5.
28. Sarewitz D. Allow use of electronic cigarettes to assess risk. Nature 2014;512:349
29. Van Pottelberge GR, Mestdagh P, Bracke KR, Thas O, van Durme YM, Joos GF, et al. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:898-906.
30. Berman ML, Connolly G, Cummings KM, Djordjevic MV, Hatsukami DK, Henningfield JE, et al. Providing a science base for the evaluation of tobacco products. Tob Regul Sci 2015;1:76-93.
31. Caramori G, Kirkham P, Barczyk A, Di Stefano A, Adcock I. Molecular pathogenesis of cigarette smoking-induced stable COPD. Ann N Y Acad Sci 2015;1340:55-64.
32. Crotty Alexander LE, Shin S, Hwang JH. Inflammatory diseases of the lung induced by conventional cigarette smoke: a review. Chest 2015;148: 1307-22.
33. Garvey C. Recent updates in chronic obstructive pulmonary disease. Postgrad Med 2016;128:231-8.
34. Gomes M, Teixeira AL, Coelho A, Araujo A, Medeiros R. The role of inflammation in lung cancer. Adv Exp Med Biol 2014;816:1-23.
35. Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Medica 2014;57:65-72.
36. Zhou Z, Chen P, Peng H. Are healthy smokers really healthy? Tob Induc Dis 2016;14:35.
37. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006;8:599-622.
38. US Department of Health and Human Services. The health consequences of smoking: 50 years of progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centres for Disease Control and Prevention, National Centre for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Available from: https://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf.
39. Office of the Surgeon General (US); Office on Smoking and Health (US). The health consequences of smoking: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2004. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20669512.
40. US Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A Report of the SurgeonGeneral. Rockville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK53017/.
41. Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 2005;31:57-82.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
43. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7.
44. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 2010;17:89-97.
45. Kitajima S, Thummalapalli R, Barbie DA. Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Semin Cell Dev Biol 2016;58:127-35.
46. Schuliga M. NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules 2015;5:1266-83.
47. Hecht SS, Kassie F, Hatsukami DK. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009;9:476-88.
48. Suthar SK, Sharma M. Recent developments in chimeric NSAIDs as anticancer agents: teaching an old dog a new trick. Mini Rev Med Chem 2016;16:1201-18.
49. Baik CS, Brasky TM, Pettinger M, Luo J, Gong Z, Wactawski-Wende J, et al. Nonsteroidal anti-inflammatory drug and aspirin use in relation to lung cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2015;24:790-7.
50. Brasky TM, Baik CS, Slatore CG, Potter JD, White E. Non-steroidal antiinflammatory drugs and small cell lung cancer risk in the VITAL study. Lung Cancer 2012;77:260-4.
51. McCormack VA, Hung RJ, Brenner DR, Bickeboller H, Rosenberger A, Muscat JE, et al. Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control 2011;22:1709-20.
52. Sekine Y, Hata A, Koh E, Hiroshima K. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment. Gen Thorac Cardiovasc Surg 2014;62:415-21.
53. Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K. Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol 2014;5:660-6.
54. Yang IA, Relan V, Wright CM, Davidson MR, Sriram KB, Savarimuthu Francis SM, et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets 2011;15:439-56.
55. Koshiol J, Rotunno M, Consonni D, Pesatori AC, De Matteis S, Goldstein AM, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS One 2009;4:e7380.
56. Zaynagetdinov R, Sherrill TP, Gleaves LA, Hunt P, Han W, McLoed AG, et al. Chronic NF-kappaB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs. Oncotarget 2016;7:5470-82.
57. Barreiro E, Bustamante V, Curull V, Gea J, Lopez-Campos JL, Munoz X. Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights. J Thorac Dis 2016;8:E1122-e35.
58. Vermaelen K, Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther 2013;26:544-54.
59. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996;9:1989-94.
60. Chaudhuri R, Livingston E, McMahon AD, Lafferty J, Fraser I, Spears M, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006;174: 127-33.
61. Westergaard CG, Porsbjerg C, Backer V. The effect of smoking cessation on airway inflammation in young asthma patients. Clin Exp Allergy 2014; 44:353-61.
62. Hogman M, Holmkvist T, Walinder R, Merilainen P, Ludviksdottir D, Hakansson L, et al. Increased nitric oxide elimination from the airways after smoking cessation. Clin Sci 2002;103:15-9.
63. Swan GE, Hodgkin JE, Roby T, Mittman C, Jacobo N, Peters J. Reversibility of airways injury over a 12-month period following smoking cessation. Chest 1992;101:607-12.
64. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26: 835-45.
65. Ravensberg AJ, Slats AM, van Wetering S, Janssen K, vanWijngaarden S, de Jeu R, et al. CD8(+) T cells characterize early smoking-related airway pathology in patients with asthma. Respir Med 2013;107: 959-66.
66. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997;155:852-7.
67. Costabel U, Bross KJ, Reuter C, Ruhle KH, Matthys H. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986;90: 39-44.
68. Lofdahl JM, Wahlstrom J, Skold CM. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol 2006; 145:428-37.
69. Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax 2003;58: 135-42.
70. Lams BE, Sousa AR, Rees PJ, Lee TH. Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease. Eur Respir J 2000;15:512-6.
71. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016;138:16-27.
72. Skold CM, Lundahl J, Hallden G, Hallgren M, Eklund A. Chronic smoke exposure alters the phenotype pattern and the metabolic response in human alveolar macrophages. Clin Exp Immunol 1996;106:108-13.
73. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 1979;97:149-206.
74. Ropcke S, Holz O, Lauer G, Muller M, Rittinghausen S, Ernst P, et al. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One 2012;7:e46207.
75. Karimi R, Tornling G, Grunewald J, Eklund A, Sköld CM. Cell recovery in bronchoalveolar lavage fluid in smokers is dependent on cumulative smoking history. PLoS ONE 2012;7:e34232.
76. Willemse BWM. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005;26: 835-45.
77. Rennard SI, Daughton D, Fujita J, Oehlerking MB, Dobson JR, Stahl MG, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J 1990;3:752-9.
78. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, Miyamoto K, et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002;57: 405-11.
79. Emami Ardestani M, Zaerin O. Role of serum interleukin 6, albumin and C-reactive protein in COPD patients. Tanaffos 2015;14:134-40.
80. Zhang L, Cheng Z, Liu W, Wu K. Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD 2013;10:459-65.
81. Bhavani S, Tsai CL, Perusich S, Hesselbacher S, Coxson H, Pandit L, et al. Clinical and immunological factors in emphysema progression. Five-year prospective longitudinal exacerbation study of chronic obstructive pulmonary disease (LES-COPD). Am J Respir Crit Care Med 2015;192:1171-8.
82. McEvoy JW, Nasir K, DeFilippis AP, Lima JA, Bluemke DA, Hundley WG, et al. Relationship of cigarette smoking with inflammation and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015;35:1002-10.
83. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 2014;106:pii:dju294.
84. Herfs M, Hubert P, Poirrier AL, Vandevenne P, Renoux V, Habraken Y, et al. Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: implications for chronic obstructive pulmonary disease therapy. Am J Respir Cell Mol Biol 2012;47:67-79.
85. Willemse BW, ten Hacken NH, Rutgers B, Postma DS, Timens W. Association of current smoking with airway inflammation in chronic obstructive pulmonary disease and asymptomatic smokers. Respir Res 2005;6:38.
86. Hacievliyagil SS, Mutlu LC, Temel I. Airway inflammatory markers in chronic obstructive pulmonary disease patients and healthy smokers. Niger J Clin Pract 2013;16:76-81.
87. Kunz LI, Lapperre TS, Snoeck-Stroband JB, Budulac SE, Timens W, van Wijngaarden S, et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 2011;12:34.
88. Steiling K, Kadar AY, Bergerat A, Flanigon J, Sridhar S, Shah V, et al. Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers. PLoS One 2009;4: e5043.
89. Tilley AE, O'Connor TP, Hackett NR, Strulovici-Barel Y, Salit J, Amoroso N, et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS One 2011;6:e22798.
90. Harvey BG, Heguy A, Leopold PL, Carolan BJ, Ferris B, Crystal RG. Modification of gene expression of the small airway epithelium in response to cigarette smoking. J Mol Med 2007;85:39-53.
91. Whitney DH, Elashoff MR, Porta-Smith K, Gower AC, Vachani A, Ferguson JS, et al. Derivation of a bronchial genomic classifier for lung cancer in a prospective study of patients undergoing diagnostic bronchoscopy. BMC Med Genomics 2015;8:18.
92. Vachani A, Whitney DH, Parsons EC, Lenburg M, Ferguson JS, Silvestri GA, et al. Clinical utility of a bronchial genomic classifier in patients with suspected lung cancer. Chest 2016;150:210-8.
93. Beane J, Vick J, Schembri F, Anderlind C, Gower A, Campbell J, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res 2011;4:803-17.
94. Strulovici-Barel Y, Omberg L, O'Mahony M, Gordon C, Hollmann C, Tilley AE, et al. Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke. Am J Respir Crit Care Med 2010;182:1524-32.
95. Wang G, Xu Z, Wang R, Al-Hijji M, Salit J, Strulovici-Barel Y, et al. Genes associated with MUC5AC expression in small airway epithelium of human smokers and non-smokers. BMC Med Genomics 2012;5:21.
96. De Smet EG, Mestdagh P, Vandesompele J, Brusselle GG, Bracke KR. Non-coding RNAs in the pathogenesis of COPD. Thorax 2015;70: 782-91.
97. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA. Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008;180: 5689-98.
98. Sato T, Liu X, Nelson A, Nakanishi M, Kanaji N, Wang X, et al. Reduced miR-146a increases prostaglandin E(2)in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med 2010;182:1020-9.
99. Zago M, Rico de Souza A, Hecht E, Rousseau S, Hamid Q, Eidelman DH, et al. The NF-kappaB family member RelB regulates microRNAmiR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts. Toxicol Lett 2014;226:107-16.
100. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103:12481-6.
101. Hassan F, Nuovo GJ, Crawford M, Boyaka PN, Kirkby S, Nana-Sinkam SP, et al. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One 2012;7:e50837.
102. Hallows KR, Fitch AC, Richardson CA, Reynolds PR, Clancy JP, Dagher PC, et al. Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. J Biol Chem 2006;281: 4231-41.
103. Zhao Y, Xu Y, Li Y, Xu W, Luo F, Wang B, et al. NF-kappaB-mediated inflammation leading to EMT via miR-200c is involved in cell transformation induced by cigarette smoke extract. Toxicol Sci 2013;135: 265-76.
104. Shen HJ, Sun YH, Zhang SJ, Jiang JX, Dong XW, Jia YL, et al. Cigarette smoke-induced alveolar epithelial-mesenchymal transition is mediated by Rac1 activation. Biochim Biophys Acta 2014; 1840:1838-49.
105. Milara J, Peiro T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients withCOPDand induced by cigarette smoke. Thorax 2013;68:410-20.
106. Sohal SS, Walters EH. Role of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD). Respir Res 2013;14:120.
107. Rippo MR, Olivieri F, Monsurro V, Prattichizzo F, Albertini MC, Procopio AD. MitomiRs in human inflamm-aging: a hypothesis involving miR-181a, miR-34a and miR-146a. Exp Gerontol 2014;56:154-63.
108. Xie L, Wu M, Lin H, Liu C, Yang H, Zhan J, et al. An increased ratio of serum miR-21 to miR-181a levels is associated with the early pathogenic process of chronic obstructive pulmonary disease in asymptomatic heavy smokers. Mol Biosyst 2014;10:1072-81.
109. Yu JH, Long L, Luo ZX, Li LM, You JR. Anti-inflammatory role of microRNA let-7c in LPS treated alveolar macrophages by targeting STAT3. Asian Pac J Trop Med 2016;9:72-5.
110. Murugan V, Peck MJ. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp Lung Res 2009; 35:439-85.
111. Graff JW, Powers LS, Dickson AM, Kim J, Reisetter AC, Hassan IH, et al. Cigarette smoking decreases global microRNA expression in human alveolar macrophages. PLoS One 2012;7:e44066.
112. Bosse Y, Postma DS, Sin DD, Lamontagne M, Couture C, Gaudreault N, et al. Molecular signature of smoking in human lung tissues. Cancer Res 2012;72:3753-63.
113. Trojanek JB, Cobos-Correa A, Diemer S, Kormann M, Schubert SC, Zhou-Suckow Z, et al. Airway mucus obstruction triggersmacrophage activation and matrix metalloproteinase 12-dependent emphysema. Am J Respir Cell Mol Biol 2014;51:709-20.
114. Wang G, Wang R, Strulovici-Barel Y, Salit J, Staudt MR, Ahmed J, et al. Persistence of smoking-induced dysregulation of miRNA expression in the small airway epithelium despite smoking cessation. PLoS One 2015;10:e0120824.
115. Osei ET, Florez-Sampedro L, Timens W, Postma DS, Heijink IH, Brandsma CA. Unravelling the complexity of COPD by microRNAs: it's a small world after all. Eur Respir J 2015;46:807-18.
116. Hsu PC, Lan RS, Brasky TM, Marian C, Cheema AK, Ressom HW, et al. Metabolomic profiles of current cigarette smokers. Mol Carcinog 2017;56:594-606.
117. Hsu PC, Lan RS, Brasky TM, Marian C, Cheema AK, Ressom HW, et al. Menthol smokers: metabolomic profiling and smoking behavior. Cancer Epidemiol Biomarkers Prev 2017;26:51-60.
118. Hsu PC, Zhou B, Zhao Y, Ressom HW, Cheema AK, Pickworth W, et al. Feasibility of identifying the tobacco-related globalmetabolome in blood by UPLC-QTOF-MS. J Proteome Res 2013;12:679-91.
119. Mathe EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res 2014; 74:3259-70.
120. Gu F, Derkach A, Freedman ND, Landi MT, Albanes D, Weinstein SJ, et al. Cigarette smoking behaviour and blood metabolomics. Int J Epidemiol 2016;45:1421-32.
121. Garcia-Perez I, Lindon JC, Minet E. Application of CE-MS to a metabonomics study of human urine from cigarette smokers and non-smokers. Bioanalysis 2014;6:2733-49.
122. Muller DC, Degen C, Scherer G, Jahreis G, Niessner R, Scherer M. Metabolomics using GC-TOF-MS followed by subsequent GC-FID and HILIC-MS/MS analysis revealed significantly altered fatty acid and phospholipid species profiles in plasma of smokers. J Chromatogr B Analyt Technol Biomed Life Sci 2014;966:117-26.
123. Xu T, Holzapfel C, Dong X, Bader E, Yu Z, Prehn C, et al. Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med 2013;11:60.
124. Kaluarachchi MR, Boulange CL, Garcia-Perez I, Lindon JC, Minet EF. Multiplatform serum metabolic phenotyping combined with pathway mapping to identify biochemical differences in smokers. Bioanalysis 2016;8:2023-43.
125. Ghosh N, Dutta M, Singh B, Banerjee R, Bhattacharyya P, Chaudhury K. Transcriptomics, proteomics and metabolomics driven biomarker discovery in COPD: an update. Expert Rev Mol Diagn 2016; 16:897-913.
126. Chen Q, Deeb RS, Ma Y, Staudt MR, Crystal RG, Gross SS. Serum metabolite biomarkers discriminate healthy smokers from COPD smokers. PLoS One 2015;10:e0143937.
127. Ren X, Zhang J, Fu X, Ma S, Wang C, Wang J, et al. LC-MS based metabolomics identification of novel biomarkers of tobacco smokeinduced chronic bronchitis. Biomed Chromatogr 2016;30:68-74.
128. Beebe K, Kennedy AD. Sharpening precision medicine by a thorough interrogation of metabolic individuality. Comput Struct Biotechnol J 2016;14:97-105.
129. Tebani A, Abily-Donval L, Afonso C, Marret S, Bekri S. Clinical metabolomics: the new metabolic window for inborn errors of metabolism investigations in the post-genomic era. Int J Mol Sci 2016;17:pii:e1167.
130. Guo L, Milburn MV, Ryals JA, Lonergan SC, Mitchell MW, Wulff JE, et al. Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci USA 2015;112:E4901-10.
131. Snyder NW, Mesaros C, Blair IA. Translational metabolomics in cancer research. Biomark Med 2015;9:821-34.
132. Conlon TM, Bartel J, Ballweg K, Gunter S, Prehn C, Krumsiek J, et al. Metabolomics screening identifies reduced L-carnitine to be associated with progressive emphysema. Clin Sci 2016;130:273-87.
133. Cameron SJ, Lewis KE, Beckmann M, Allison GG, Ghosal R, Lewis PD, et al. The metabolomic detection of lung cancer biomarkers in sputum. Lung Cancer 2016;94:88-95.
134. Surowiec I, KarimpourM, Gouveia-Figueira S, Wu J, Unosson J, Bosson JA, et al. Multi-platform metabolomics assays for human lung lavage fluids in an air pollution exposure study. Anal Bioanal Chem 2016; 408:4751-64.
135. Malerba M, Montuschi P. Non-invasive biomarkers of lung inflammation in smoking subjects. Curr Med Chem 2012;19:187-96.
136. See KC, Christiani DC. Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population: results from the National Health and Nutrition Examination Survey 2007-2010. Chest 2013;143:107-16.
137. Smith AD, Cowan JO, Taylor DR. Exhaled nitric oxide levels in asthma: personal best versus reference values. J Allergy Clin Immunol 2009; 124:714-814.
138. Smith B, D'Costa J. Review: medication adjustment based on fractional exhaled nitric oxide did not prevent asthma exacerbations. Evid Based Med 2009;14:8.
139. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxidemeasurements to guide treatment in chronic asthma. N Engl J Med 2005;352:2163-73.
140. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev 2016; 11:Cd011439.
141. Kim JK, Jung JY, Kim H, Eom SY, Hahn YS. Combined use of fractional exhaled nitric oxide and bronchodilator response in predicting future loss of asthma control among children with atopic asthma. Respirology 2016;22:466-72.
142. Redington AE. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006;533:263-76.
143. Hillas G, Kostikas K, Mantzouranis K, Bessa V, Kontogianni K, Papadaki G, et al. Exhaled nitric oxide and exhaled breath condensate pH as predictors of sputum cell counts in optimally treated asthmatic smokers. Respirology 2011;16:811-8.
144. Pietropaoli AP, Perillo IB, Perkins PT, Frasier LM, Speers DM, Frampton MW, et al. Smokers have reduced nitric oxide production by conducting airways but normal levels in the alveoli. Inhal Toxicol 2007;19:533-41.
145. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995;152:609-12.
146. Xu X, Hu H, Kearney GD, Kan H, Carrillo G, Chen X. A populationbased study of smoking, serum cotinine and exhaled nitric oxide among asthmatics and a healthy population in the USA. Inhal Toxicol 2016;28:724-30.
147. Jones KL, Bryan TW, Jinkins PA, Simpson KL, Grisham MB, Owens MW, et al. Superoxide released from neutrophils causes a reduction in nitric oxide gas. Am J Physiol 1998;275(6 Pt 1):L1120-6.
148. Rytila P, Rehn T, Ilumets H, Rouhos A, Sovijarvi A, Myllarniemi M, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006;7:69.
149. Lerner CA, Sundar IK, Watson RM, Elder A, Jones R, Done D, et al. Environmental health hazards of e-cigarettes and their components: oxidants and copper in e-cigarette aerosols. Environ Pollut 2015;198: 100-7.
150. U.S. Food and Drug Administration. 2016 generally recognized as safe (GRAS). Available from: http://www.fda.gov/Food/IngredientsPackagin gLabeling/GRAS/.
151. Park SJ, Walser TC, Perdomo C, Wang T, Pagano PC, Liclican EL, et al. Abstract B16: The effect of e-cigarette exposure on airway epithelial cell gene expression and transformation. Clin Cancer Res 2014; 20(2 Suppl):B16-B.
152. Sinjewel A, Swart EL, Lingeman H, Wilhelm AJ. LC determination of propylene glycol in human plasma after pre-column derivatization with benzoyl chloride. Chromatographia 2007;66:103-5.
153. Holćapek M, Virelizier H, Chamot-Rooke J, Jandera P, Moulin C. Trace determination of glycols by HPLC with UV and electrospray ionization mass spectrometric detections. Anal Chem 1999;71:2288-93.
154. McIntosh TS, Davis HM, Matthews DE. A liquid chromatography-mass spectrometry method to measure stable isotopic tracer enrichments of glycerol and glucose in human serum. Anal Biochem 2002;300:163-9.
155. Kosmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res 2014;16:1319-26.
156. Sleiman M, Logue JM, Montesinos VN, Russell ML, Litter MI, Gundel LA, et al. Emissions from electronic cigarettes: key parameters affecting the release of harmful chemicals. Environ Sci Technol 2016;50:9644-51.
157. Uchiyama S, Senoo Y, Hayashida H, Inaba Y, Nakagome H, Kunugita N. Determination of chemical compounds generated from secondgeneration E-cigarettes using a sorbent cartridge followed by a twostep elution method. Anal Sci 2016;32:549-55.
158. Herrington JS, Myers C. Electronic cigarette solutions and resultant aerosol profiles. J Chromatogr A 2015;1418:192-9.
159. Flora JW, Meruva N, Huang CB, Wilkinson CT, Ballentine R, Smith DC, et al. Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. Regul Toxicol Pharmacol 2016;74:1-11.
160. Department of Health and Human Services. FDA Federal Register; 2014. https://www.federalregister.gov/documents/2016/05/10/2016-10685/deeming-tobacco-products-to-be-subject-to-the-federal-fooddrug-and-cosmetic-act-as-amended-by-the
161. World Health Organisation. Conference of the Parties to the WHO Framework Convention on Tobacco Control, Report by WHO; 2014. http://www.who.int/fctc/cop/sessions/COP6-report-FINAL-04122014.pdf?ua=1.
162. Grana RA, Popova L, Ling PM. A longitudinal analysis of electronic cigarette use and smoking cessation. JAMA Intern Med 2014;174:812.
163. Adzersen KH, Becker N, Steindorf K, Frentzel-Beyme R. Cancer mortality in a cohort of male German iron foundry workers. Am J Ind Med 2003; 43:295-305.
164. World Health Organisation. World Health Assembly Resolution 561, (2015); 2015. Available from: http://www.who.int/tobacco/framework/final-text/en/.
165. Cressey D. E-cigarettes: the lingering questions. Nature 2014;513:24-6.
166. More on hidden formaldehyde in E-cigarette aerosols. N Engl J Med 2015; 372:1575-7. http://www.nejm.org/doi/full/10.1056/nejmc1502242.
167. Cheng T. Chemical evaluation of electronic cigarettes. Tob Control 2014;23 Suppl 2:ii11-ii7.
168. Burstyn I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 2014;14:18.
169. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014;23:133-9.
170. Orr MS. Electronic cigarettes in the USA: a summary of available toxicology data and suggestions for the future: Table 1. Tob Control 2014; 23 Suppl 2:ii18-ii22.
171. Tayyarah R, Long GA. Comparison of select analytes in aerosol from ecigarettes with smoke from conventional cigarettes and with ambient air. Regul Toxicol Pharmacol 2014;70:704-10.
172. Bekki K, Uchiyama S, Ohta K, Inaba Y, Nakagome H, Kunugita N. Carbonyl compounds generated from electronic cigarettes. Int J Environ Res Public Health 2014;11:11192-200.
173. Hutzler C, Paschke M, Kruschinski S, Henkler F, Hahn J, Luch A. Chemical hazards present in liquids and vapors of electronic cigarettes. Arch Toxicol 2014;88:1295-308.
174. Kosmider L, Sobczak A, Prokopowicz A, Kurek J, Zaciera M, Knysak J, et al. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. Thorax 2016;71:376-7.
175. Kim YH, Kim KH. A novel method to quantify the emission and conversion of VOCs in the smoking of electronic cigarettes. Sci Rep 2015; 5:16383.
176. Leigh NJ, Lawton RI, Hershberger PA, Goniewicz ML. Flavourings significantly affect inhalation toxicity of aerosol generated from electronic nicotine delivery systems (ENDS). Tob Control 2016; 25 Suppl 2:ii81-ii7.
177. Gillman IG, Kistler KA, Stewart EW, Paolantonio AR. Effect of variable power levels on the yield of total aerosolmass and formation of aldehydes in e-cigarette aerosols. Regul Toxicol Pharmacol 2016;75:58-65.
178. Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med 2015;372:392-4.
179. Geiss O, Bianchi I, Barrero-Moreno J. Correlation of volatile carbonyl yields emitted by e-cigarettes with the temperature of the heating coil and the perceived sensorial quality of the generated vapours. Int J Hyg Environ Health 2016;219:268-77.
180. Havel CM, Benowitz NL, Jacob P III, St Helen G. An electronic cigarette vaping machine for the characterization of aerosol delivery and composition. Nicotine Tob Res 2016; PMID: 27281605.
181. Pisinger C, Døssing M. A systematic review of health effects of electronic cigarettes. Prev Med 2014;69:248-60.
182. Hiemstra PS, Bals R. Basic science of electronic cigarettes: assessment in cell culture and in vivo models. Respir Res 2016;17:127.
183. Misra M, Leverette R, Cooper B, Bennett M, Brown S. Comparative in vitro toxicity profile of electronic and tobacco cigarettes, smokeless tobacco and nicotine replacement therapy products: E-liquids, extracts and collected aerosols. Int J Environ Res Public Health 2014;11:11325-47.
184. Husari A, Shihadeh A, Talih S, Hashem Y, El Sabban M, Zaatari G. Acute exposure to electronic and combustible cigarette aerosols: effects in an animal model and in human alveolar cells. Nicotine Tob Res 2016; 18:613-9.
185. Schweitzer KS, Chen SX, Law S, Van Demark M, Poirier C, Justice MJ, et al. Endothelial disruptive proinflammatory effects of nicotine and ecigarette vapor exposures. Am J Physiol Lung Cell Mol Physiol 2015; 309:L175-87.
186. Scheffler S, Dieken H, Krischenowski O, Forster C, Branscheid D, Aufderheide M. Evaluation of E-cigarette liquid vapor and mainstream cigarette smoke after direct exposure of primary human bronchial epithelial cells. Int J Environ Res Public Health 2015;12:3915-25.
187. Scheffler S, Dieken H, Krischenowski O, Aufderheide M. Cytotoxic evaluation of e-liquid aerosol using different lung-derived cell models. Int J Environ Res Public Health 2015;12:12466-74.
188. Higham A, Rattray NJ, Dewhurst JA, Trivedi DK, Fowler SJ, Goodacre R, et al. Electronic cigarette exposure triggers neutrophil inflammatory responses. Respir Res 2016;17:56.
189. Yu V, Rahimy M, Korrapati A, Xuan Y, Zou AE, Krishnan AR, et al. Electronic cigarettes induce DNA strand breaks and cell death independently of nicotine in cell lines. Oral Oncol 2016;52:58-65.
190. Holliday R, Kist R, Bauld L. E-cigarette vapour is not inert and exposure can lead to cell damage. Evid Based Dent 2016;17:2-3.
191. Thorne D, Crooks I, Hollings M, Seymour A, Meredith C, Gaca M. The mutagenic assessment of an electronic-cigarette and reference cigarette smoke using the Ames assay in strains TA98 and TA100. Mutat Res 2016;812:29-38.
192. Garcia-Arcos I, Geraghty P, Baumlin N, Campos M, Dabo AJ, Jundi B, et al. Chronic electronic cigarette exposure inmice induces features ofCOPDin a nicotine-dependent manner. Thorax 2016;71:1119-29.
193. Wu Q, Jiang D, Minor M, Chu HW. Electronic cigarette liquid increases inflammation and virus infection in primary human airway epithelial cells. PLoS One 2014;9:e108342.
194. Lerner CA, Rutagarama P, Ahmad T, Sundar IK, Elder A, Rahman I. Electronic cigarette aerosols and copper nanoparticles induce mitochondrial stress and promoteDNAfragmentation in lung fibroblasts. Biochem Biophys Res Commun 2016;477:620-5.
195. Shen Y, Wolkowicz MJ, Kotova T, Fan L, Timko MP. Transcriptome sequencing reveals e-cigarette vapor and mainstream-smoke from tobacco cigarettes activate different gene expression profiles in human bronchial epithelial cells. Sci Rep 2016;6:23984.
196. Javed F, Kellesarian SV, Sundar IK, Romanos GE, Rahman I. Recent updates on electronic cigarette aerosol and inhaled nicotine effects on periodontal and pulmonary tissues. Oral Dis 2017; PMID: 28168771 .
197. Suber RL, Deskin R, Nikiforov I, Fouillet X, Coggins CR. Subchronic noseonly inhalation study of propylene glycol in Sprague-Dawley rats. Food Chem Toxicol 1989;27:573-83.
198. Final report on the safety assessment of Ricinus Communis (Castor) Seed Oil, Hydrogenated Castor Oil, Glyceryl Ricinoleate, Glyceryl Ricinoleate SE, Ricinoleic Acid, Potassium Ricinoleate, Sodium Ricinoleate, Zinc Ricinoleate, Cetyl Ricinoleate, Ethyl Ricinoleate, Glycol Ricinoleate, Isopropyl Ricinoleate, Methyl Ricinoleate, andOctyldodecyl Ricinoleate. Int J Toxicol 2007;26 Suppl 3:31-77.
199. Renne RA, Wehner AP, Greenspan BJ, DeFord HS, Ragan HA, Westerberg RB, et al. 2-week and 13-week inhalation studies of aerosolized glycerol in rats. Inhal Toxicol 1992;4:95-111.
200. Werley MS, McDonald P, Lilly P, Kirkpatrick D, Wallery J, Byron P, et al. Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs. Toxicology 2011;287:76-90.
201. Lim HB, Kim SH. Inhallation of e-cigarette cartridge solution aggravates allergen-induced airway inflammation and hyper-responsiveness in mice. Toxicol Res 2014;30:13-8.
202. Lerner CA, Sundar IK, YaoH, Gerloff J, Ossip DJ, McIntosh S, et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One 2015;10:e0116732.
203. Callahan-Lyon P. Electronic cigarettes: human health effects. Tob Control 2014;23 suppl 2:ii36-ii40.
204. Hureaux J, Drouet M, Urban T. A case report of subacute bronchial toxicity induced by an electronic cigarette: Table 1. Thorax 2014;69: 596-7.
205. Usuku K, Nishizawa M, Matsuki K, Tokunaga K, Takahashi K, Eiraku N, et al. Association of a particular amino acid sequence of the HLA-DR b1 chain with HTLV-I-associated myelopathy. Eur J Immunol 1990;20: 1603-6.
206. Orr KK, Asal NJ. Efficacy of electronic cigarettes for smoking cessation. Ann Pharmacother 2014;48:1502-6.
207. Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regul Toxicol Pharmacol 2016;81 Suppl 1:S1-S14.
208. Walele T, Sharma G, Savioz R, Martin C, Williams J. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part B: Safety and subjective effects. Regul Toxicol Pharmacol 2016;74:193-9.
209. Manzoli L, Flacco ME, Ferrante M, La Vecchia C, Siliquini R, Ricciardi W, et al. Cohort study of electronic cigarette use: effectiveness and safety at 24 months. Tob Control 2017;26:284-92.
210. Cibella F, Campagna D, Caponnetto P, AmaradioMD, Caruso M, Russo C, et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clin Sci 2016;130: 1929-37.
211. McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, et al. Electronic-cigarette use and respiratory symptoms in adolescents. Am J Respir Crit Care Med 2017;195:1043-9.
212. Polosa R, Morjaria JB, Caponnetto P, Caruso M, Campagna D, Amaradio MD, et al. Persisting long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. Discov Med 2016;21:99-108.
213. Polosa R, Morjaria JB, Caponnetto P, Prosperini U, Russo C, Pennisi A, et al. Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. Respir Res 2016;17:166.
214. Goniewicz ML, Gawron M, Smith DM, Peng M, Jacob P III, Benowitz NL. Exposure to nicotine and selected toxicants in cigarette smokers who switched to electronic cigarettes: a longitudinal within-subjects observational study. Nicotine Tob Res 2017;19:160-7.
215. McRobbie H, Phillips A, Goniewicz ML, Smith KM, Knight-West O, Przulj D, et al. Effects of switching to electronic cigarettes with and without concurrent smoking on exposure to nicotine, carbon monoxide, and acrolein. Cancer Prev Res 2015;8:873-8.
216. Pulvers K, Emami AS, Nollen NL, Romero DR, Strong DR, Benowitz NL, et al. Tobacco consumption and toxicant exposure of cigarette smokers using electronic cigarettes. Nicotine Tob Res. 2016 Dec 21. [Epub ahead of print].
217. O'Connell G, Graff DW, D'Ruiz CD. Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers. Toxicol Mech Methods 2016;26:443-54.
218. D'Ruiz CD, Graff DW, Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health 2016;16:543.
219. Campagna D, Cibella F, Caponnetto P, Amaradio MD, Caruso M, Morjaria JB, et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. Eur J Clin Investig 2016; 46:698-706.
220. Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, et al. Nicotine, carcinogen, and toxin exposure in long-term E-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med 2017;166:390-400.
221. Jorenby DE, Smith SS, Fiore MC, Baker TB. Nicotine levels, withdrawal symptoms, and smoking reduction success in real world use: a comparison of cigarette smokers and dual users of both cigarettes and E-cigarettes. Drug Alcohol Depend 2017;170:93-101.
222. Marini S, Buonanno G, Stabile L, Avino P. A benchmark for numerical scheme validation of airborne particle exposure in street canyons. Environ Sci Pollut Res 2015;22:2051-63.
223. Vardavas CI, Anagnostopoulos N, Kougias M, Evangelopoulou V, Connolly GN, Behrakis PK. Short-term pulmonary effects of using an electronic cigarette: impact on respiratory flow resistance, impedance, and exhaled nitric oxide. Chest 2012;141:1400-6.
224. FerrariM, Zanasi A, Nardi E, Morselli Labate AM, Ceriana P, Balestrino A, et al. Short-term effects of a nicotine-free e-cigarette compared to a traditional cigarette in smokers and non-smokers. BMC Pulm Med 2015;15:120.
225. Schober W, Szendrei K, Matzen W, Osiander-Fuchs H, Heitmann D, Schettgen T, et al. Use of electronic cigarettes (e-cigarettes) impairs indoor air quality and increases FeNO levels of e-cigarette consumers. Int J Hyg Environ Health 2014;217:628-37.
226. Harrell MB, Weaver SR, Loukas A, Creamer M, Marti CN, Jackson CD, et al. Flavored e-cigarette use: characterizing youth, young adult, and adult users. Prev Med Rep 2017;5:33-40.
227. Bonhomme MG, Holder-Hayes E, Ambrose BK, Tworek C, Feirman SP, King BA, et al. Flavoured non-cigarette tobacco product use among US adults: 2013-2014. Tob Control 2016;25 Suppl 2:ii4-ii13.
228. Hoffman AC, Salgado RV, Dresler C, Faller RW, Bartlett C. Flavour preferences in youth versus adults: a review. Tob Control 2016;25 Suppl 2:ii32-ii9.
229. Allen JG, Flanigan SS, LeBlanc M, Vallarino J, MacNaughton P, Stewart JH, et al. Flavoring chemicals in E-cigarettes: diacetyl, 2, 3-pentanedione, and acetoin in a sample of 51 products, including fruit-, candy-, and cocktail-flavored E-cigarettes. Environ Health Perspect 2016;124: 733-9.
230. Farsalinos KE, Kistler KA, Gillman G, Voudris V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. Nicotine Tob Res 2015;17:168-74.
231. Khlystov A, Samburova V. Flavoring compounds dominate toxic aldehyde production during E-cigarette vaping. Environ Sci Technol 2016; 50:13080-5.
232. Sherwood CL, Boitano S. Airway epithelial cell exposure to distinct ecigarette liquid flavorings reveals toxicity thresholds and activation of CFTR by the chocolate flavoring 2, 5-dimethypyrazine. Respir Res 2016;17:57.
233. Behar RZ, Davis B, Wang Y, Bahl V, Lin S, Talbot P. Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro 2013;28:198-208.
234. Bahl V, Lin S, Xu N, Davis B, WangYH, Talbot P. Comparison of electronic cigarette refill fluid cytotoxicity using embryonic and adult models. Reprod Toxicol 2012;34:529-37.
235. Werley MS, Kirkpatrick DJ, Oldham MJ, Jerome AM, Langston TB, Lilly PD, et al. Toxicological assessment of a prototype e-cigaret device and three flavor formulations: a 90-day inhalation study in rats. Inhal Toxicol 2016;28:22-38.
236. U.S. Food and Drug Administration. Menthol Cigarettes and Public Health: Review of the Scientific Evidence and Recommendations; 2011. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisory Committee/ucm247605.htm.
237. Hoffman AC. The health effects of menthol cigarettes as compared to nonmenthol cigarettes. Tob Induc Dis 2011;9 Suppl 1:S7.
238. Gerloff J, Sundar IK, Freter R, Sekera ER, Friedman AE, Robinson R, et al. Inflammatory response and barrier dysfunction by different e-cigarette flavoring chemicals identified by gas chromatography-mass spectrometry in e-liquids and e-vapors on human lung epithelial cells and fibroblasts. Appl In Vitro Toxicol 2017;3:28-40.
239. Cardinale A, Nastrucci C, Cesario A, Russo P. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol 2012;42:68-89.
240. Shields PG. Long-term nicotine replacement therapy: cancer risk in context. Cancer Prev Res 2011;4:1719-23.
241. Sorensen LT, Toft B, Rygaard J, Ladelund S, Teisner B, Gottrup F. Smoking attenuates wound inflammation and proliferation while smoking cessation restores inflammation but not proliferation. Wound Repair Regen 2010;18:186-92.
242. Li Q, Zhou X, Kolosov VP, Perelman JM. Nicotine suppresses inflammatory factors in HBE16 airway epithelial cells after exposure to cigarette smoke extract and lipopolysaccharide. Transl Res 2010; 156:326-34.
243. Tsoyi K, Jang HJ, Kim JW, Chang HK, Lee YS, Pae HO, et al. Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine attenuates inflammatory response in macrophages and improves survival in experimental model of sepsis through heme oxygenase-1 induction. Antioxid Redox Signal 2011;14:2057-70.
244. Goncalves RB, Coletta RD, Silverio KG, Benevides L, Casati MZ, da Silva JS, et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res 2011;60:409-24.
245. Lunney PC, Leong RW. Review article: Ulcerative colitis, smoking and nicotine therapy. Aliment Pharmacol Ther 2012;36:997-1008.
246. Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury. Inflammation 2011;34:231-7.
247. Comer DM, Elborn JS, Ennis M. Inflammatory and cytotoxic effects of acrolein, nicotine, acetylaldehyde and cigarette smoke extract on human nasal epithelial cells. BMC Pulm Med 2014;14:32.
248. Lam DC, Luo SY, Fu KH, Lui MM, Chan KH, Wistuba II, et al. Nicotinic acetylcholine receptor expression in human airway correlates with lung function. Am J Physiol Lung Cell Mol Physiol 2016; 310:L232-9.
249. Vukelic M, Qing X, Redecha P, Koo G, Salmon JE. Cholinergic receptors modulate immune complex-induced inflammation in vitro and in vivo. J Immunol 2013;191:1800-7.
250. Baez-Pagan CA, Delgado-Velez M, Lasalde-Dominicci JA. Activation of the macrophage alpha7 nicotinic acetylcholine receptor and control of inflammation. J Neuroimmune Pharmacol 2015;10:468-76.
251. Zhou MS, Chadipiralla K, Mendez AJ, Jaimes EA, Silverstein RL, Webster K, et al. Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling. Am J Physiol Heart Circ Physiol 2013;305:H563-74.
252. Wang Y, Zhang F, Yang W, Xue S. Nicotine induces pro-inflammatory response in aortic vascular smooth muscle cells through a NFkappaB/osteopontin amplification loop-dependent pathway. Inflammation 2012;35:342-9.
253. Yang X, Zhao C, Gao Z, Su X. A novel regulator of lung inflammation and immunity: pulmonary parasympathetic inflammatory reflex. Qjm 2014;107:789-92.
254. Nizri E, Brenner T. Modulation of inflammatory pathways by the immune cholinergic system. Amino Acids 2013;45:73-85.
255. Treinin M, Papke RL, Nizri E, Ben-David Y, Mizrachi T, Brenner T. Role of the alpha7 nicotinic acetylcholine receptor and RIC-3 in the cholinergic anti-inflammatory pathway. Cent Nerv Syst Agents Med Chem 2016.
256. Filippini P, Cesario A, Fini M, Locatelli F, Rutella S. The Yin and Yang of non-neuronal alpha7-nicotinic receptors in inflammation and autoimmunity. Curr Drug Targets 2012;13:644-55.
257. Hayashi S, Hamada T, Zaidi SF, Oshiro M, Lee J, Yamamoto T, et al. Nicotine suppresses acute colitis and colonic tumorigenesis associated with chronic colitis in mice. Am J Physiol Gastrointest Liver Physiol 2014;307:G968-78.
258. El Dib R, Suzumura EA, Akl EA, Gomaa H, Agarwal A, Chang Y, et al. Electronic nicotine delivery systems and/or electronic non-nicotine delivery systems for tobacco smoking cessation or reduction: a systematic review and meta-analysis. BMJ Open 2017;7:e012680.
259. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review andmeta-analysis. Lancet Respir Med 2016;4:116-28.
260. Kim V, Oros M, Durra H, Kelsen S, AksoyM, Cornwell WD, et al. Chronic bronchitis and current smoking are associated with more goblet cells in moderate to severeCOPDand smokers without airflowobstruction. PLoS One 2015;10:e0116108.
261. Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 2009;33:352-9.
262. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 2000;278:L906-13.
263. Mancini NM, Bene MC, Gerard H, Chabot F, Faure G, Polu JM, et al. Early effects of short-time cigarette smoking on the human lung: a study of bronchoalveolar lavage fluids. Lung 1993;171:277-91.
264. Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group, Kunz LIZ, Lapperre TS, Snoeck-Stroband JB, Budulac SE, TimensW, et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res 2011;12:34.
265. Wen Y, Reid DW, Zhang D, Ward C, Wood-Baker R, Walters EH. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Int J Chron Obstruct Pulmon Dis 2010;5:327-34.
266. Klech H, Hutter C. Side-effects and safety of BAL. Eur Respir J 1990;3: 939-40.
267. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control 2001;10:189-95.
268. Shields PG. Tobacco smoking, harm reduction, and biomarkers. J Natl Cancer Inst 2002;94:1435-44.
269. Levy DT, Cummings KM, Villanti AC, Niaura R, Abrams DB, Fong GT, et al. A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products. Addiction 2017;112:8-17.
270. Chen J, Bullen C, Dirks K. A comparative health risk assessment of electronic cigarettes and conventional cigarettes. Int J Environ Res Public Health 2017;14:pii:E382.
271. Baumung C, Rehm J, Franke H, Lachenmeier DW. Comparative risk assessment of tobacco smoke constituents using the margin of exposure approach: the neglected contribution of nicotine. Sci Rep 2016;6:35577.